"Skin rashes" and immunotherapy in melanoma: distinct dermatologic adverse events and implications for therapeutic management

Immune checkpoint inhibitors have shown efficacy in the treatment of different cancers by stimulating the antitumoral activity of the patient's immune system, representing a major breakthrough in the field of cancer therapy. Monoclonal antibodies including anti-cytotoxic T-lymphocyte-associated...

Full description

Saved in:

Bibliographic Details
Published in:	Human vaccines & immunotherapeutics Vol. 18; no. 3; p. 1889449
Main Authors:	Sollena, Pietro, Cappilli, Simone, Federico, Francesco, Schinzari, Giovanni, Tortora, Giampaolo, Peris, Ketty
Format:	Journal Article
Language:	English
Published:	United States Taylor & Francis 31.05.2022 Taylor & Francis Group
Subjects:	Advanced melanoma Antibodies, Monoclonal - adverse effects Antineoplastic Agents, Immunological - adverse effects CTLA-4 Antigen - antagonists & inhibitors CTLA-4 inhibitors cutaneous adverse events Exanthema - chemically induced Humans immune checkpoint inhibitors Immunotherapy - adverse effects Melanoma - drug therapy Melanoma – Mini-Review PD-1 inhibitors skin rash skin rash cutaneous adverse events PD-1 inhibitors immune checkpoint inhibitors Advanced melanoma CTLA-4 inhibitors
ISSN:	2164-5515, 2164-554X, 2164-554X
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!